

ISAAC P. WITZ - LIST OF PUBLICATIONS

1. Pikovski, M.A. and Witz, I. Antigenic composition of normal tissues and tumors in an inbred strain of mice, *Acta Un. Int. Cancer*, 17:244-251, 1961.
2. Pikovski, M.A. and Witz, I. Antigenic composition of normal tissues and tumors in an inbred strain of mice. Changes in certain globulins associated with tumor growth. *Br. J. Cancer* 15:584-593, 1961.
3. Pikovski, M.A., Witz, I. and Tenenbaum, E. Precipitins and cytotoxins in antiurine sera. *Acta U. Int. Cancrum*. 19:181-182, 1961.
4. Pikovski, M.A., Witz, I. and Tenenbaum, E. Cytotoxic action of anti-urine sera on mouse tumor cells. *Nature*, 198:1314-1316, 1963.
5. Witz, I., Hermann, G., Pikovski, M.A. and Gross, J. The Antigenic composition of tumors, sera and urines of tumor-bearing mice and partial purification of two antigens present in increased amounts. *Br. J. Cancer*, 18:397-406, 1964.
6. Witz, I. and Gross, J. The purification and partial characterization of mouse hemopexin (Beta 2 - III Globulin). *Proc. Soc. Exptl. Biol. and Med.*, 118:1003-1006, 1965.
7. Witz, I., Yagi, Y. and Pressman, D. IgG associated with microsomes from autochthonous hepatomas and normal liver of rats. *Cancer Res.* 27: 2295-2299, 1967.
8. Witz, I., Yagi, Y. and Pressman, D. Immunosuppressive activity of rabbit antisera directed against mouse lymphocytic leukemia L1210. *Proc. Soc. Exptl. Biol. and Med.* 127:562-565, 1968.
9. Witz, I., Yagi, Y. and Pressman, D. Availability of isoantigens to circulating antibodies. *J. Immunol.* 101:217-223, 1968.
10. Witz, I., Yagi, Y. and Pressman, D. A normal component in rabbit IgG with affinity for mouse tissues. *Immunology*, 15:765-772, 1968.
11. Witz, I., Kaliss, N. and Pressman, D. Isoantigens available to circulating antibodies. *J. Immunol.* 102:283-287, 1969.
12. Witz, I., Yagi, Y. and Pressman, D. Brain localizing activity of hetero and isoimmune sera directed against lymphocytic cells. *Proc. Soc. Exptl. Biol. and Med.* 130:928-930, 1969.
13. Witz, I., Klein, G. and Pressman, D. Moloney lymphoma antibodies from mice: Localization in spleens of moloney lymphoma bearing mice. *Proc. Soc. Exptl. Biol. and Med.* 130:1102-1105, 1969.
14. Witz, I., Cudkowicz, G. and Pressman, D. Availability of transplantation alloantigens to circulating antibodies: Studies with alloantibodies of known specificity. *J. Immunol.* 102:1373-1378, 1969.
15. Witz, I., Chiampi, N.P. and Kaliss, N. Immunosuppressive activity of mouse alloantibodies. *Transplantation*, 8:516-518, 1969.
16. Witz, I., Cudkowicz, G. and Pressman, D. Detection of hemopoietic allografts by localization of radiolabeled alloantibodies. *J. Immunol.* 104:19-22, 1970.
17. Witz, I. and Ran, M. Studies on the association of immunoglobulins with tumors. In: *Immunity and Tolerance in Oncogenesis*. L. Severi Ed. Division of Cancer Research, Perugia, Italy, pp. 345-354, 1970.
18. Ran, M. and Witz, I.P. Tumor associated immunoglobulins. The elution of IgG from mouse tumors. *Int. J. Cancer*, 6:361-372, 1970.
19. Witz, I.P. Tumor associated immunoglobulins. *Israel J. Med. Sci.* 7: 230-238, 1971.
20. Maor, D. and Witz, I.P. Increased ribonuclease activity in thymus and lymph-nodes after intraperitoneal antigenic stimulation with sheep erythrocytes. *Immunology*, 20: 259-261, 1971.
21. Witz, I., Chiampi, N.P., Samuel, T. and Kaliss, N. Suppression of the immune response by alloantibodies. In: *The Properties and Mode of Action of Anti-Lymphocyte Serum*. B. Halpern, ed. pp. 355-359, 1971.

22. Witz, I.P., Kaliss, N. and Samuel, T. The Immunosuppressive capacity of alloantisera in mice, including sera directed primarily against thymic antigen. *Cellular Immunol.* 2: 362-372, 1971.
23. Ran, M. and Witz, I.P. Tumor associated immunoglobulins. Enhancement of syngeneic tumors by IgG2 containing tumor eluates. *Int. J. Cancer* 9: 242-247, 1972.
24. Handzel, Z.T., Frensdorff, A., Buchner, V.C. and Witz, I.P. The ability of thymus and bone marrow cells from immunized donors to restore antibody formation to BSA in irradiated mice. *Immunology*, 23: 651-653, 1972.
25. Witz, I.P., Harness, E. and Pikovski, M.A. Suppressed plaque and rosette formation by spleen cells of mice injected with tumor extract. In: *Microenvironmental Aspects of Immunity*, ed. B.D. Jankovic and K. Isakovic, Plenum Publishing Co., New York, pp. 461-568, 1972.
26. Witz, I.P. The Biological Significance of tumor bound immunoglobulins. *Current topics in microbiology and immunology*, 61: 151-171, 1973.
27. Keisari, Y. and Witz, I.P. Degradation of mouse immunoglobulins by lysosomal enzymes of mouse tumors. *Immunochemistry*, 10: 565-570, 1973.
28. Witz, I.P., Kinamon, S., Ran, M. and Klein, G. Tumor bound immunoglobulins. The *in vitro* fixation of radioiodine labeled anti-immunoglobulin reagents by mouse tumor cells. *Clin. Exp. Immunol.* 16 : 321-333, 1974.
29. Ran, M., Fish, F., Witz, I.P. and Klein, G. Tumor bound immunoglobulins. The *in vitro* disappearance of immunoglobulin from the surface of coated tumor cells and some properties of released materials. *Clin. Exp. Immunol.*, 16: 335-353, 1974.
30. Fish, F., Witz, I.P. and Klein, G. Tumor-bound immunoglobulins. The fate of IgG disappearing from the surface of coated tumor cells. *Clin. Exp. Immunol.* 16:355-365, 1974.
31. Witz, I.P., Levy, H.J., Keisari, Y. and Izsak, F. Ch. Tumor-bound immunoglobulins. Their possible role in circumventing anti-tumor immunity. In: "The Role of Immunological Factors in Viral and Oncogenic Processes". Edited by R.S. Beers, R.C. Tilghman and B.G. Basset, John Hopkins University Press, Baltimore, pp. 289-300, 1974.
32. Izsak, F. Ch., Brenner, H.J., Landes, E., Ran, M. and Witz, I.P. The malignant potential of human tumors - A clinical-histopathological evaluation, correlated with cell surface immunoglobulins. *Israel J. Med. Sci.*, 10: 642-646, 1974.
33. Dauphinee, M.J., Talal, N. and Witz, I.P. Generation of non-complement- fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies. *J. Immunol.* 113: 948-953, 1974.
34. Ran, M., Witz, I.P., Landes, E., Brenner, H.J. and Izsak, F. Ch. Immunoglobulin coating of human cancer cells; Correlation with clinical behaviour. *Excerpta Medica, International Congress Series No. 321, Characterization of Human Tumours*, 244-249, 1974.
35. Maor, D., Eylan, E. and Witz, I.P. Alkaline ribonuclease activity in lymphoid organs of mice after injection of tumor cells. *Cancer*, 34: 1940-1942, 1974.
36. Fish, F., Yaakubovicz, M. and Witz, I.P. Incorporation of ¹²⁵I-iodo- deoxyuridine into target cells as an assay for cellular immunity. *J.Nat. Cancer Inst.* 53: 1743-1747, 1974.
37. Sugai, S., Palmer, D.W., Talal, N. and Witz, I.P. Protective and cellular immune responses to idiotypic membrane determinants on cells from a spontaneous lymphoma on NZB/NZW F₁ mice. *J. Exp. Med.* 140: 1547-1558, 1974.
38. Keisari, Y. and Witz, I.P. Degradation of xenogeneic cytotoxic anti- tumor antibodies by tumor-derived lysosomal enzymes and the generation of products blocking humoral cytotoxicity. *Behring Inst. Mitt.* 56: 19-27, 1975.
39. Pikovski, M.A., Ziffroni-Gallon, Y. and Witz, I.P. Suppression of the immune response to SRBC in mice treated with preparations of a tumor cell component and in tumor-bearing mice. *Europ. J. Immunol.* 5: 447-450, 1975.

40. Ran, M., Eshel, I., Witz, I.P. and Klein, G. Dynamic alterations in some surface properties of freshly explanted moloney lymphoma cells. *J. Nat. Cancer Inst.* 55: 843-849, 1975.
41. Keisari, Y. and Witz, I.P. The specific blocking of humoral immune cytotoxicity mediated by anti-tumor antibodies degraded by lysosomal enzymes of tumor origin. *Europ. J. Immunol.* 5: 790-795, 1975.
42. Tracey, D.E., Witz, I.P., Pross, H.F. and Jondal, M. Antibody-dependent cell-mediated cytotoxic activity in syngeneic mouse ascites tumors. *Int. J. Cancer*, 16: 870-880, 1975.
43. Witz, I.P., Dauphinee, M.J. and Talal, N. The blocking activity of anti-tumor alloantibodies treated with tumor derived lysosomal extracts. *Transpl. Proc.* 7: suppl. 1. 483-484, 1975.
44. Talal, N., Sugai, S. and Witz, I.P. Monoclonal IgM as a tumor specific transplantation antigen. *Transpl. Proc.* 7: suppl. 1. 505-507, 1975.
45. Ran, M., Klein, G. and Witz, I.P. Tumor-bound immunoglobulins. Evidence for the *in-vivo* coating of tumor cells by potentially cytotoxic anti-tumor antibodies. *Int. J. Cancer* 17: 90-97, 1976.
46. Dorval, G., Witz, I.P., Klein, E. and Witzell, H. Tumor-bound immunoglobulins. Further analysis of the characteristics of binding of immunoglobulins to *in-vivo* growing tumor cells. *Int. J. Cancer* 17: 109-119, 1976.
47. Ran, M., Witz, I.P. and Klein, G. The *in-vivo* coating of tumor cells by potentially cytotoxic anti-tumor antibodies. In: "Immune Reactivity of Lymphocytes: Development, Expression and Control". M. Feldman and A. Globerson, Eds. Plenum Press, New York, pp. 451-456, 1976.
48. Braslawsky, G.R., Yaakubowicz, M., Frensdorff, A. and Witz, I.P. The presence of cells expressing immune complex receptors in non-lymphoid murine tumors. In: "Immune Reactivity of Lymphocytes: Development, Expression and Control". M. Feldman and A. Globerson, Eds. Plenum Press, New York, pp. 495-500, 1976.
49. Dorval, G., Witz, I.P., Klein, E. and Witzell, M. Tumor-bound immunoglobulins. An *in-vivo* phenomenon of masked specificity. *J. Nat. Cancer Inst.* 56:523-527, 1976.
50. Caspi, R. and Witz, I.P. The Effect of short-term culture on the sensitivity of MDAY murine tumor cells to lysis mediated by normal rabbit serum. *Eur. J. Immunol.* 6:174-179, 1976.
51. Braslawsky, G.R., Yaakubowicz, M., Frensdorff, A. and Witz, I.P. Receptors for immune complexes on cells within a non-lymphoid murine tumor. *J. Immunol.* 116:1571-1578, 1976.
52. Yefenof, E., Witz, I.P. and Klein, E. Interaction of antibody and cell surface localized antigens. *Int. J. Cancer*, 17:633-639, 1976.
53. Braslawsky, G.R., Ran, M. and Witz, I.P. Tumor-bound immunoglobulins. In: "The Relationship between the *in-vivo* Coating of Tumor Cells by Potentially Cytotoxic Anti-tumor Antibodies, and the Expression of Immune Complex Receptors". *Int. J. Cancer*, 18:116-121, 1976.
54. Witz, I.P., Lee, N. and Klein, G. Serologically detectable specific and cross-reactive antigens on the membrane of a Polyoma-virus induced murine tumor. *Int. J. Cancer*, 18:243-249, 1976.
55. Braslawsky, G.R., Serban, D. and Witz, I.P. Receptors for immune complexes on cells within a Polyoma-virus induced murine sarcoma. *Eur. J. Immunol.* 6:579-583, 1976.
56. Witz, I.P., Anavi, R. and Weisenbeck, H. A Tissue-binding factor in the serum of schizophrenic patients. In: "The Impact of Biology on Modern Psychiatry". Gershon, E., Belmaker, R., Ketty, S. and Rosenbaum, M. Eds. Plenum Press, New York, pp. 113-124, 1977.
57. Baron, M., Stern, M., Anavi, R. and Witz, I.P. Tissue-serum affinity in schizophrenia. A clinical and genetic study. *Biol. Psychiatry*, 12: 199-219, 1977.

58. Witz, I.P. Tumor-bound immunoglobulins. In-situ expression of tumor immunity. *Adv. Cancer Res.* 25:95-148, 1977.
59. Ran, M., Yaakubowicz, M. and Witz, I.P. Lymphocytotoxic auto antibodies eluted from *in-vivo* propagating sarcoma cells. *J. Natl. Cancer Inst.* 60:1509-1513, 1978.
60. Ran, M., Yaakubowicz, M., Talal, N. and Witz, I.P. The Relationship of membrane antigens on 141 (NZB) and EL-4 (C57B1) lymphoma cells as demonstrated by antibody-induced resistance to complement-mediated cytotoxicity. *Eur. J. Immunol.* 8:423-428, 1978.
61. Moav, N., Hochberg, Y., Cohen, G. and Witz, I.P. Binding patterns of immunoglobulins from tumor-bearing mice to the corresponding tumor cell. *J. Immunol. Meth.* 22:37-49, 1978.
62. Moav, N. and Witz, I.P. Characterization of immunoglobulins eluted from murine tumor cells: Binding patterns of cytotoxic anti-tumor IgG. *J. Immunol. Meth.* 22:51-62, 1978.
63. Anavi, R., Baron, M. and Witz, I.P. Serologic studies on schizophrenic patients. In: *Birth Defects. Original Article Series. Vol. 14*:297-309, 1978.
64. Keisari, Y. and Witz, I.P. The degradation of cell-bound antibodies by tumor cells. *J. Natl. Cancer Inst.* 61:1135-1141, 1978.
65. Serban, D., Ran, M. and Witz, I.P. Idiotype-binding cells in plasmacytoma-bearing mice. *Cellular Immunol.* 44:1-8, 1979.
66. Ran, M., Yaakubowicz, M. and Witz, I.P. *In-situ* expressions of humoral immunity within a Polyoma-virus induced tumor. In: "Antiviral Mechanisms in the Control of Neoplasia". P. Chandra, Ed. Plenum Press, New York, pp. 355-371, 1979.
67. Ehrlich, R. and Witz, I.P. The elution of antibodies from viable murine tumor cells. *J. Immunol. Meth.* 26:345-353, 1979.
68. Klein, G., Ehlin, B. and Witz, I.P. Serological detection of a Polyoma tumor-associated membrane antigen. *Int. J. Cancer*, 23:683-690, 1979.
69. Keisari, Y. and Witz, I.P. Tumor-cell mediated degradation *in-vitro* of anti-tumor antibodies. In: "Modern Trends in Human Leukemia III", R. Neth, Ed., Springer Verlag, Heidelberg. pp. 407-412, 1979.
70. Witz, I.P. Review of immunological aspects of leukemia. In: "Modern Trends in Human Leukemia III", R. Neth, Ed., Springer Verlag, Heidelberg. pp. 417-420, 1979.
71. Jurjus, A., Wheeler, D., Gallo, R.C. and Witz, I.P. Placenta-bound immunoglobulins. *Arth. Rheum.* 22:1308-1313, 1979.
72. Russell, S.W., Witz, I.P. and Herberman, R.B. A review of data, problems and open questions pertaining to in-situ tumor immunity. *Cont. Topics. Immunobiol.* 10:1-20, 1980.
73. Ran, M., Yaakubowicz, M., Amitai, O. and Witz, I.P. Tumor localizing lymphocytotoxic antibodies. *Cont. Topics Immunobiol.* 10:191-211, 1980.
74. Ehrlich, R., Efrati, M. and Witz, I.P. Characteristics of natural cytostatic effector cells. In: "Natural cell mediated immunity against tumors". R.B. Herberman (Ed.). Academic Press, pp. 47-58, 1980.
75. Ehrlich, R., Efrati, M. and Witz, I.P. Cytotoxicity and cytostasis mediated by splenocytes of mice subjected to chemical carcinogens and of mice bearing primary tumors. In: "Natural cell mediated immunity against tumors". R.B. Herberman (Ed.). Academic Press, pp. 997-1010, 1980.
76. Ehrlich, R., Efrati, M., Bar-Eyal, A., Wollberg, M., Schiby, G., Ran, M. and Witz, I.P. Natural cellular reactivities mediated by splenocytes from mice bearing three types of primary tumor. *Int. J. Cancer* 26:315-323, 1980.
77. Ehrlich, R., Efrati, M. and Witz, I.P. Some characteristics of natural cytostatic mouse splenocytes. *J. Immunol. Meth.* 40:193-208, 1980.
78. Levi, B., Witz, I.P., Malkinson, M., Singer, N., Wiseman, Y. and Ron, E.Z. Development of a multivalent live vaccine active against a wide range of enterobacteriaceae. In: "New Developments with Human and Veterinary Vaccines". Alan R. Liss, Inc., New York, pp. 119-123, 1980.

79. Baniyash, M., Netanel, T. and Witz, I.P. Differences in cell density associated with differences in lung-colonizing ability of B16 melanoma cells. *Cancer Res.* 41:433-437, 1981.
80. Netanel, T., Kinsky, R., Moav, N., Brown, R., Ran, M. and Witz, I.P. Separation of tumor seeking small lymphocytes and tumor cells using Percoll velocity gradients. *J. Immunol. Meth.* 41:43-56, 1981.
81. Serban, D., Pages, J.M., Bussard, A.E. and Witz, I.P. The participation of trimethylammonium in the mouse erythrocyte epitope recognized by monoclonal autoantibodies. *Immunol. Letters* 3:315-319, 1981.
82. Moav, N., Smorodinsky, N.I., Balin, B.A. and Witz, I.P. Monoclonal antibodies from mice bearing a polyoma virus induced tumor. *Cancer Immunol. Immunoth.* 12:217-224, 1982.
83. Malatzky, E., Ehrlich, R., Finkler, A., Koltin, Y. and Witz, I.P. Reconstitution of suppressed NK activity in DMBA-treated mice by poly I:C and natural dsRNA. In: "Current Concepts in Human Immunology and Cancer Immunomodulation", B. Serrou et al. (Eds.), Elsevier Biomedical Press, B.V., pp. 371-378, 1982.
84. Ehrlich, R., Efrati, M. and Witz, I.P. Further studies on the cytostatic activity mediated by murine splenocytes. In: "NK cells and other natural effector cells.", R.B. Herberman (Ed.), Academic Press, N.Y., pp. 201-208, 1982.
85. Ehrlich, R., Malatzky, E., Efrati, M. and Witz, I.P. The suppression of NK activity by the chemical carcinogen dimethylbenzanthracene and its restoration by Interferon or poly I:C. In: "NK Cells and Other Natural Effector Cells", R.B. Herberman (Ed.), Academic Press, N.Y., pp. 1431-1436, 1982.
86. Baniyash, M., Smorodinsky, N.I., Yaakubovicz, M. and Witz, I.P. Serologically detectable MHC and tumor associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors. *J. Immunol.* 129:1318-1323, 1982.
87. Pages, J., Poncet, P., Serban, D., Witz, I.P. and Bussard, A.E. Relationship between choline derivatives and mouse erythrocyte membrane antigens revealed by mouse monoclonal antibodies. I. Anticholine activity of anti mouse erythrocyte monoclonal antibodies. *Immunol. Lett.*, 5:167- 173, 1982.
88. Witz, I.P., Ehrlich, R., Malatzky, E. and Efrati, M.A. A depressed NK activity during the latency period of tumors induced by DMBA and its restoration. *Adv. Pathol.* Pergamon Press, Oxford, pp. 299-303, 1982.
89. Ehrlich, R. and Witz, I.P. Natural killer cells and naturally occurring antibodies as representatives of natural tumor immunity. *Pathobiol. Ann.* 12:85-113, 1982.
90. Ran, M., Lakonishuk, M., Bachar, E. and Witz, I.P. Some characteristics of non-immunoglobulin components in low pH extracts of a non-lymphoid tumor. In: "Biochemical and Biological Markers of Neoplastic Transformation", P. Chandra (Ed.), Plenum Press, N.Y., pp. 97-110, 1982.
91. Ehrlich, R., Efrati, M., Malatzky, E., Shochat, L., Bar-Eyal, A. and Witz, I.P. Natural host defence during oncogenesis, NK activity and dimethylbenzanthracene carcinogenesis. *Int. J. Cancer* 31:67-73, 1983.
92. Ehrlich, R., Efrati, M., Gonen, B., Shochat, L. and Witz, I.P. Natural cellular defence activity against tumors - cytostasis and NK activity. In: "Modern Trends in Human Leukemia", E. Neth. et al. (Eds.), Springer Verlag, Heidelberg, pp. 470-471, 1983.
93. Balin, A., Aladjem, M., Baniyash, M., Boichis, H., Barzilay, Z., Gal, R. and Witz, I.P. The effect of lithium chloride on tumor appearance and survival of melanoma-bearing mice. *Br. J. Cancer*, 48:83-87, 1983.
94. Ran, M. and Witz, I.P. The significance of tumor associated anti T cell antibodies for tumor-host immune relationship. *Leukemia Rev.*, 2:151-171, 1984.
95. Witz, I.P., Yaakubovicz, M., Gelernter, I., Hochberg, Y., Anavi, R. and Ran, M. Studies on the level of natural antibodies reactive with various tumor cells during urethan carcinogenesis in BALB/c mice. *Immunobiol.* 166:131-145, 1984.

96. Ran, M., Dux, Z., Anavi, R., Smorodinsky, N.I. and Witz, I.P. A radioimmunoassay for the detection of antigenic cell-free Fc receptors using monoclonal antibodies. *J. Immunol. Meth.* 68:275-284, 1984.
97. Khayat, D., Dux, Z., Anavi, R., Shlomo, Y., Witz, I.P. and Ran, M. Circulating cell free Fc 2/ 1 Receptor in normal mouse serum - Its detection and specificity. *J. Immunol.* 132: 2496-2501, 1984.
98. Ehrlich, R., Smorodinsky, N., Efrati, M., Yaakubovicz., M. and Witz, I.P. B16 melanoma development, NK activity cytoxicity and natural antibodies in 3 and 12 months old mice. *Brit. J. Cancer* 49:769-777, 1984.
99. Ran, M., Dux, Z., Anavi, R. and Witz, I.P. Expression of Fc γ receptor on a subpopulation of non-lymphoid tumor cells and its enrichment. *J. Natl. Cancer Inst.* 73:437-445, 1984.
100. Witz, I.P. and Meyer, G. Membrane antigens associated with infection, transformation and tumorigenesis by polyoma virus. *Cancer Immunol. Immunoth.* 17: 147-153, 1984.
101. Jurjus, A.R., Ridgeway, A. and Witz, I.P. 2' Deoxycoformycin and human hemopoietic cells in culture. *Develop. Comp. Immunol.* 9: 931-937, 1984.
102. Witz, I.P., Efrati, M., Ehrlich, R., Gonen, B., Cahalon, L., Sagi, O., Sahar, E., Shochat, L., Smorodinsky, N.I., Yaakov, S., Yaakubowicz, M. and Yron, I. Natural defence and chemical carcinogenesis. In: "Modern Trends in Human Leukemia." Edited by: R. Neth et al., Springer Verlag, Heidelberg, pp. 492- 498, 1985.
103. Witz, I.P. and Ran, M. Could Fc-Receptors facilitate the escape of immunogenic premalignant cells from host defence? A hypothesis. *Ann. Inst. Pasteur* 136C: 423-428, 1985.
104. Ran, M. and Witz, I.P. FcR derived from without the immune system - A Potential escape mechanism for cells propagating in a hostile immunological environment. *Gynec. Obstet.* 14: 9-14, 1985.
105. Yron, I., Schickler, M., Fisch, B., Pinkas, H., Ovadia, J. and Witz, I.P. The immune system during the precancer and the early cancer period. IL-2 production by PBL from postmenopausal women with and without endometrial carcinoma. *Int. J. Cancer*.38:331-338, 1986.
106. Ehrlich, R., Gonen, B., Sahar, E., Efrati, M., Smorodinsky, N., Shochat, L., Sagi, O. and Witz, I.P. The immunity system during the precancer period. Marker and function analysis of NK and alloreactive T cells during early stages of DMBA carcinogenesis. *Nat. Imm. Cell Growth Reg.* 5: 305-316, 1986.
107. Witz, I.P., Agassy-Cahalon, L., Fisch, B., Lidor, Y., Ovadia, Y., Pinkas, H., Ran, M., Schickler, M., Smorodinsky, N., Sredni, B., and Yron, I. Immune reactivities during the precancer and early cancer periods. Novel approaches for immunomodulation. In: *New experimental modalities in the control of neoplasia.* ed: P. Chandra, Plenum Press, 71-80, 1986.
108. Witz, I.P. and Agassy-Cahalon, L. Do naturally occurring antibodies play a role in the progression and proliferation of tumor cells? *Intern. Rev. Immunol.* 3: 133-145, 1987.
109. Douer, D., Sagi, O., Sahar, E. and Witz, I.P. Immune functions and hematopoietic progenitor cell activity in plasmacytoma-bearing mice cured by melphalan. In: "Modern trends in human leukemia VII". Edited by: R. Neth, et al., Springer-Verlag, Heidelberg, pp.360-361, 1987.
110. Smorodinsky, N.I., Cahalon, L., Argov, S., Witz, I.P. and Shoenfeld, Y. Naturally-occurring tumor-reactive autoantibodies: A monoclonal antibody from normal mice reacts with tumor cells and with DNA. *Immun. Lett.* 18:43-50, 1988.
111. Sagi, O., Witz, I.P., Ramot, B., Sahar, E. and Douer, D. Late immune and hematopoietic functions in plasmacytoma-bearing mice cured by melphalan. *Br. J. Cancer* 57:271-276, 1988.
112. Agassy-Cahalon, L., Yaakubowicz, M., Witz, I.P. and Smorodinsky N.I. The immune system during the precancer period. Naturally occurring tumor-reactive monoclonal antibodies and urethan carcinogenesis. *Immun. Lett.* 18:181-190, 1988.

113. Serban, D. and Witz, I.P. Further Studies on the determinant recognized by naturally-occurring murine autoantibodies reacting with bromelain-treated erythrocytes. *Immun. Lett.* **18**:191-200, 1988.
114. Gonen, B., Ran, M., Wreschner, D., Cahalon, L., Anavi, R., Shlomo, Y. and Witz, I.P. Some immunological properties of high and low tumorigenic cellular variants of C-H-ras transformed 3T3 cells. *Nat. Imm. Cell Growth Reg.* **7**:144-154, 1988.
115. Ran, M., Teillaud, J.L., Fridman, W.H., Frenkel, H., Halachmi, E., Katz, B-Z., Gibbs, M., Shlomo, Y., Barzilay, J. and Witz, I.P. Increased expression of Fc receptors in cancer patients and tumor-bearing mice. *Molec. Immunol.* **25**:1159-1167, 1988.
116. Yron, I., Ehrlich, R., Efrati, M., Shohat, L., Witz, I.P. and Sahar, E. Comparison of NK activity in mouse spleen and peripheral blood lymphocytes. *Immunobiol.* **117**:449-460, 1988.
117. Witz, I.P., Cahalon, L., Smorodinsky, N.I. and Ran, M. The bearing of certain tumors may result in autoimmunity. *Isr. J. Med. Sci.* **24**:744-746, 1988.
118. Halachmi, E. and Witz, I.P. Differential tumorigenicity of 3T3 cells transformed in-vitro with Polyoma virus and the in-vivo selection for high tumorigenicity. *Cancer Res.* **49**:2383-2389, 1989.
119. Sagi, O., Witz, I.P., Shaked, N., Ramot, B. and Douer, D. The in-vivo effects of recombinant GM-CSF on neutropenia and survival of mice treated with a high dose of melphalan. *Eur. J. Haematol.* **43**:240-244, 1989.
120. Berko-Flint, Y., Fridman, W.H., Grossman-Atlas, E., Kimchi, N., Langer-Ben Baruch, A., Moss, S., Teillaud, J-L., Witz, I.P. and Ran, M. Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. *Mol. Immunol.* **27**:1219-1228, 1990.
121. Yron, I., Langer, A., Weinstein, T., Sahar, E., Lidor, Y., Pardo, Y., Katz, B., Shohat, L., Kalechman, Y., Ovadia, J., Witz, I.P. and Sredni, B. Effect of sex hormones on human T cell activation by concanavalin A. *Nat. Immun. Cell Growth Regul.* **10**:32-44, 1991.
122. Ran, M., Katz, B., Kimchi, N., Halachmi, E., Teillaud, J-L., Even, J., Berko, Y., Atlas, E., Fridman, W.H. and Witz, I.P. The in-vivo acquisition of Fc γ RII expression on polyomas virus transformed cells derived from tumors of long latency. *Cancer Res.* **51**:612-618, 1991.
123. Stein, R., Witz, I.P., Ovadia, J., Goldenberg, D.M. and Yron, I. CD5-positive B cells and naturally occurring autoantibodies in cancer patients. *Clin. Exp. Immunol.* **85**:418-423, 1991.
124. Fisch, B., Rikover, Y., Shohat, L., Zurgil, N., Tadir, Y., Ovadia, J., Witz, I.P. and Yron, I. The relationship between in vitro fertilization and naturally occurring antibodies; Evidence for increased production of antiphospholipid antibodies. *Fertility and Sterility* **56**: 718-724, 1991.
125. Cahalon, L., Korem, S., Puri, Y., Smorodinsky, N.I. and Witz, I.P. Regulation of tumor growth and immunomodulation mediated by naturally-occurring autoantibodies. *Ann. N.Y. Acad. Sci.* **651**: 393-408, 1992.
126. Yron, I., Tadir, Y., Ovadia, J., Zurgil, N., Firer, M., Witz, I.P. and Fisch, B. Evidence for increased levels of circulating antiphospholipid autoantibodies in patients undergoing in-vitro fertilization treatment. *Ann. N.Y. Acad. Sci.* **651**: 599-601, 1992.
127. Witz, I.P. The involvement of Fc receptors in tumor progression. *AIDS Res. Hum. Retroviruses* **8**: 806-811, 1992.
128. Ben-Baruch Langer, A., Emmanuel, N., Even, J., Fridman, W.H., Gohar, O., Gonen, B., Katz, B-Z., Ran, M., Smorodinsky, N.I. and Witz, I. P. Phenotypic properties of 3T3 cells transformed in vitro with polyoma virus and passaged once in syngeneic animals. *Immunobiol.* **185**: 281-291, 1992.
129. Ran, M., Ben-Baruch Langer, A., Eliassi, I., Gohar, O., Gonen, B., Gradsztajn, S., Fridman, W.H., Teillaud, J-L. and Witz, I.P. Possibilities of interference with the immune system of tumor bearers by non lymphoid Fc γ RII expressing tumor cells. *Immunobiol.* **185**: 415-425 1992.

130. Gonen, B., Kahana, O. and Witz, I.P. In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factor mediated killing of c-Ha-ras- transformed cells. *Cancer Immunol. Immunother.* **35**: 388-394, 1992.
131. Witz, I.P. and Ran, M. FcR may function as a progression factor of non-lymphoid tumors. *Immunol. Res.* **11**: 283-295, 1992.
132. Witz, I.P. Naturally Occurring Antibodies and Tumor Development and Progression. In: "Natural Autoantibodies. Their Physiological Role and Regulatory Significance". Edited by: Y. Shoenfeld and D.A. Isenberg, CRC Press, New York, pp. 248-256, 1992.
133. Katz, B-Z. and Witz, I.P. The in-vitro exposure of polyoma-virus transformed cells to laminin augments their in-vivo malignancy phenotype. *Invasion Metastasis* **13**: 185-194, 1993.
134. Sagi-Assif, O., Douer, D., Shaked, N., Russell, S.W. and Witz, I.P. Myeloproliferation in long-term plasmacytoma regressor mice. *Int. J. Cancer* **56**: 208-213, 1994.
135. Yron, I., Shohat, L., Lahav, J., Witz, I.P. and Fisch, B. A human monoclonal IgA Autoantibody - 185/12 - behaves like an autoimmune antiphospholipid antibody. *Clin. Exp. Immunol.* **97**: 187-192, 1994.
136. Katz, B-Z., Eshel, R., Sagi-Assif, O. and Witz, I.P. An association between a high Ly-6A/E expression on tumor cells and a high malignancy phenotype. *Int. J. Cancer* **59**: 684-691, 1994.
137. Katz, B.-Z., Ishai-Michaeli, R., Zusman, T., Vlodaysky, I. and Witz, I.P. Lung colonization by and heparanase activity in in-vitro transformed 3T3 cells rendered highly tumorigenic by an in-vivo passage. *Invasion Metast.* **14**: 276-289, 1994-95.
138. Eshel, R., Firon, M., Katz, B.-Z., Sagi-Assif, O., Aviram, H. and Witz, I.P. Microenvironmental factors regulate Ly-6 A/E expression by PyV-transformed BALB/c 3T3 cells. *Immunol. Lett.* **44**: 209-212, 1995
139. Fisch, B., Peled, Y., Fried, S., Ovadia, J., Witz, I.P. and Yron, I. Detection of immunoglobulin A cardiolipin antibodies in cervical mucus from in-vitro fertilization patients and fertile women. *Fertility and Sterility* **64**: 441-443, 1995.
140. Fisch, B., Fried, S., Manor, Y., Ovadia, J., Witz, I.P. and Yron, I. Increased antiphospholipid antibody activity in in-vitro fertilization patients is not treatment-dependent but rather an inherent characteristic of the infertile state. *Amer. J. Reprod. Immunol.* **34**: 370-374, 1995.
141. Zusman, T., Gohar, O., Eliassi, I., Avivi, Y., Lisansky, E., Sautes, C., Even, J., Bonnerot, C., Fridman, W.H., Witz, I.P. and Ran, M. The murine Fc-gamma (Fc γ) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus-transformed 3T3 cells. *Int. J. Cancer* **65**: 221-229, 1996.
142. Witz, I.P., Sagi-Assif, O. and Ran, M. The shaping of the malignancy phenotype - An interplay between cellular characteristics and microenvironmental factors. In: *Premalignancy and Tumor Dormancy.* (Eitan Yefenof and Richard H. Scheuermann, Eds.) Medical Intelligence Unit, R.G. Landes Co., pp. 147-156, 1996.
143. Zusman, T., Lisansky, E., Arons, E., Anavi, R., Bonnerot, C., Sautes, C., Fridman, W.H., Witz, I.P. and Ran, M. The contribution of the intracellular domain of the murine Fc-gamma receptor type II B1 to its tumor enhancing potential. *Int. J. Cancer*, **67**: 1-9, 1996.
144. Witz, I.P. The shaping of a malignancy phenotype by microenvironmental host factors. In: *Recent Advances in Gastroenterological Carcinogenesis I.* F. Tahara, K. Sugimachi and T. Oohara, Eds. Monduzzi Editore Bologna, pp. 287-294, 1996
145. Sagi-Assif, O., Treister, A., Katz, B.-Z., Anavi, R., Eskenasy, M. and Witz, I.P. TNF α and anti Fas antibodies regulate Ly-6E.1 expression by tumor cells. A possible link between angiogenesis and Ly-6E.1. *Immunol. Lett.* **54**: 207-213, 1996.
146. Sagi-Assif, O., Trakhtenbrot, L., Douer, D. and Witz, I.P. Preleukemia in long-term plasmacytoma-regressor mice. *Int. J. Cancer* **76**: 689-693, 1998.
147. Treister, A., Sagi-Assif, O., Meer, M., Smorodinsky, N.I., Anavi, R., Golan, I., Meshel, T., Kahana, O., Eshel, R., Katz, B-Z., Shevach, E. and Witz, I.P. Expression of Ly-6, a

- marker for highly malignant murine tumor cells, is regulated by growth conditions and stress. *Int. J. Cancer* **77**: 306-313, 1998.
148. Neumark, E., Anavi, R., Witz, I.P. and Ben-Baruch, A. MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. *Imm. Lett.* **68**: 141-146, 1999.
 149. Sagi-Assif, O., Douer, D. and Witz, I.P. Cytokine network imbalances in plasmacytoma- regressor mice. *Curr. Top. Microbiol. Immunol.* **246**: 395-401, 1999.
 150. Witz, I.P. The differential expression of genes by tumor cells of a low or a high malignancy phenotype. The case of murine and human Ly-6 proteins. *J. Cell. Biochem. Supp.* **34**:61-66, 2000.
 151. Eshel, R., Zanin, A., Sagi-Assif, O., Meshel, T., Smorodinsky, N.I., Dwir, O., Alon, R., Brakenhoff, R., van Dongen, G. and Witz, I.P. The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX-enzyme and of E-selectin ligands on Head and Neck Squamous Carcinoma Cells. *J. Biol. Chem.* **275**: 12833-12840, 2000.
 152. Geminder H, Sagi-Assif O, Goldberg L, Meshel T, Rechavi G, Witz IP, and Ben-Baruch A. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. *J Immunol.* **167**: 4747-4757, 2001.
 153. Witz, I.P. Presence and functions of immune components in the tumor microenvironment. *Progress in Basic and Clinical Immunology. Adv Exp Med Biol.* **495**: 317-324, 2001.
 154. Eshel, R., Besser, M., Zanin, A., Sagi-Assif, O., and Witz, I.P. The FX enzyme is a functional component of lymphocyte activation. *Cell. Immunol.* **213**: 141-148, 2001.
 155. Eshel, R., Zanin, A., Kapon, D., Sagi-Assif, O., Brakenhoff, R., van Dongen, G. and Witz, I.P. The human Ly-6 antigen E48 (Ly-6D) regulates important interaction parameters between endothelial cells and head and neck squamous carcinoma cells. *Int. J Cancer* **98**: 803-810, 2002.
 156. Neumark, E., Cohn, M.A., Lukanidin, E., Witz, I.P. and Ben-Baruch, A. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. *Immunol. Letters* **82**: 111-121, 2002.
 157. Witz, I.P. The tumour microenvironment - Introduction. *Semin Cancer Biol.* **12**: 87-88, 2002.
 158. Eshel, R., Neumark, E., Sagi-Assif, O., and Witz, I.P. Receptors involved in microenvironment-driven molecular evolution of cancer cells. *Semin. Cancer Biol.* **12**: 139-47, 2002.
 159. Kahana, O., Micksche, M., Witz, I.P. and Yron, I. The focal adhesion kinase (P125^{FAK}) is constitutively active in human malignant melanoma. *Oncogene* **21**: 3969-3977, 2002.
 160. Izraeli, S., Witz, I. and Micksche, M. Cancer research--from bench to bedside. *Isr. Med. Assoc. J.* **4**: 746-748, 2002.
 161. Levy-Nissenbaum, O., Sagi-Assif, O., Hantisteanu, S., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. PYST2, a MAPK dual specificity phosphatase is regulated by microenvironmental factors. *Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria.* Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 11-17, 2002.
 162. Kahana, O., Micksche, M., Witz, I.P. and Yron, I. The possible role of focal adhesion kinase (P125^{FAK}) in the malignancy of human melanoma. *Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria.* Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 89-94, 2002.
 163. Hantisteanu, S., Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. Adherence up regulates expression of PYST2-L in myeloid leukemia cells. *Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria.* Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 95-100, 2002.

164. Neumark, E., Witz, I.P. and Ben-Baruch, A. Mammary adenocarcinoma progression: potential role of inter-relationships between MCP-1, GM-CSF and TNF alpha. Proc. 2nd Int. Conf. on Tumor Microenvironment, Progression, Therapy and Prevention, Baden, Austria. Isaac P. Witz, Ed., Monduzzi Editore, S.p.A., Bologna, Italy, pp. 109-114, 2002.
165. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. cDNA microarray analysis reveals an over expression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Meth. Enzymology, 366:103-113, 2003.
166. Neumark, E., Sagi-Assif, O., Shalmon, B., Ben-Baruch, A. and Witz, I.P. Progression of mouse mammary tumors: MCP-1-TNF α cross-regulatory pathway and clonal expression of pro-malignancy and anti-malignancy factors. Int. J. Cancer, 106: 879-868, 2003.
167. Levy-Nissenbaum, O., Sagi-Assif, O., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. Over expression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Cancer Letters, 199: 185-192, 2003.
168. Levy-Nissenbaum, O., Sagi-Assif, O., Kapon, D., Hantisteanu, S., Burg, T., Raanani, P., Avigdor, A., Ben-Bassat, I. and Witz, I.P. The dual-specificity phosphatase PYST2 is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene, 22: 7649-60, 2003.
169. Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I, Witz IP. cDNA microarray analysis reveals an overexpression of the dual-specificity MAPK phosphatase PYST2 in acute leukemia. Methods Enzymol. 366:103-113, 2003.
170. Levy-Nissenbaum O, Sagi-Assif O, Witz IP. Characterization of the dual-specificity phosphatase PYST2 and its transcripts. Genes Chromosomes Cancer. 39: 37-47, 2004.
171. Levy-Nissenbaum O, Barak E, Burg TG, Sagi-Assif O., Kloog Y, Witz IP. Does the dual-specificity MAPK phosphatase Pyst2-L lead a monogamous relationship with the Erk2 protein? Immunol Lett. 92: 149-156, 2004.
172. Nevo I, Sagi-Assif O, Meshel T, Geminder H, Goldberg-Bittman L, Ben-Menachem S, Shalmon B, Goldberg I, Ben-Baruch A, Witz IP. The tumor microenvironment: CXCR4 is associated with distinct protein expression patterns in neuroblastoma cells. Immunol Lett. 92: 163-169, 2004.
173. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A. The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunol Lett. 92: 171-178, 2004.
174. Zipin A, Israeli-Amit M, Meshel T, Sagi-Assif O, Yron I, Lifshitz V, Bacharach E, Smorodinsky NI, Many A, Czernilofsky PA, Morton DL, Witz IP. Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res. 2004 64: 6571-6578.
175. Goldberg-Bittman L, Sagi-Assif O, Meshel T, Nevo I, Levy-Nissenbaum O, Yron I, Witz IP, Ben-Baruch A. Cellular characteristics of neuroblastoma cells: regulation by the ELR(-)-CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine. 29: 105-117, 2005.
176. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol. Lett. 104: 89-93, 2006.
177. Levy-Nissenbaum O, Ben-Menachem S, Sagi-Assif O, Witz IP. The Pyst2-L phosphatase is involved in cell-crowding. Immunol. Lett. 104: 138-145, 2006.
178. Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 130: 125-140, 2006.
179. Witz IP, Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Lett. 242: 1-10, 2006.

180. Zipin A, Meshel T, Sagi-Assif O, Shalmon B, Witz IP, Ben-Baruch A. CXCL10 promotes invasion-related properties in colorectal carcinoma cells. *Cancer Res.* 67: 3396-405, 2007.
181. Lifshitz V, Chen-Levi L, Zipin-Roitman A, Meshel T, Sagi-Assif O, Levi-Nissenbaum O, Witz IP, Yron I. The tumour microenvironment regulates components of the fucose biosynthesis pathways in colorectal cancer cells. In: Gasche C, Gassull M, Herrerias Gutierrez JM, Monterio E, editors. *Intestinal Inflammation and Colorectal Cancer.* Heidelberg: Springer. 294-305, 2007.
182. Ben David T, Sagi-Assif O, Meshel T, Yron I and Witz IP. The Involvement of the Sialyl Lewis-A Selectin Ligand in the Extravasation of Human Colorectal Carcinoma Cells. *Immunol. Letters*, 116: 218-24. 2007.
183. Witz IP Yin-yang activities and vicious cycles in the tumor microenvironment. *Cancer Res.* 68: 9-13, 2008.
184. Witz IP The Role of the Selectin-Selectin Ligand Axis in Tumor Progression. *Cancer Metastasis Rev.* 27: 10-30, 2008
185. Aychek T, Miller K, Sagi-Assif O, Israeli-Amit M, Levi-Nissenbaum O, Pasmanik-Chor M, Jacob-Hirsch J, Amariglio N, Rechavi G and Witz IP. E-Selectin Regulates Gene Expression in Metastatic Colorectal Carcinoma Cells and enhances HMGB1 Release. *Int J Cancer*, 123: 1741-1750, 2008.
186. Witz IP Tumor- Microenvironment Interactions: Dangerous Liaisons. *Adv. Cancer Res.* 100: 203-229, 2008.
187. Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva, L, Schwab M, Yron I and Witz IP. Generation and Characterization of Novel Local and Metastatic Human Neuroblastoma Variants. *Neoplasia*, 10: 816-827, 2008.
188. Nevo I, Sagi-Assif O, Meshel T, Ben-Baruch A, Jöhrer K, Leider Trejo L, Kharenko O, Yron I and Witz IP. The Involvement of Fractalkine Receptor in Bone Marrow-Endothelium Transmigration of Neuroblastoma Cells. *Cancer Letters*, 273: 127-139, 2009
189. Witz IP. The Tumor Microenvironment: Making of a Paradigm. *Cancer Microenvironment*, Suppl 1:9-17, 2009
190. Nevo I, Oberthuer A, Edri-Botzer L, Sagi-Assif O, Maman S, Pasmanik-Chor M, Kariv N, Fischer M, Yron I and Witz IP. Gene-Expression-Based Analysis of Local and Metastatic Neuroblastoma Variants Reveals a Set of Genes Associated with Metastatic Progression. *Int. J. Cancer*, 126: 1570-81, 2010
191. Izraely S, Klein A, Sagi-Assif O, Meshel T, Tsarfaty G, Hoon DS, Witz IP. Chemokine-chemokine receptor axes in melanoma brain metastasis. *Immunol Lett.* 130:107-14, 2010.
192. Mohla, S. and Witz, IP. The 5th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention, *Cancer Microenvironment* 3: 1-5, 2010
193. Vidal-Vanaclocha F and Witz IP. Introducing the cancer microenvironment section of *Journal of Translational Medicine.* *J Transl Med.* 8:60, 2010
194. Edry Botzer L, Maman S, Sagi-Assif O, Meshel T, Nevo I, Bäuerle T, Yron I, Witz IP. Lung-Residing Metastatic and Dormant Neuroblastoma Cells. *Am J Pathol*; 179:524-36. 2011
195. Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud, PO, Ateh E, Bryant JL, Hoon DSB, Witz IP. The Metastatic Microenvironment. Brain Residing Melanoma Metastasis and Dormant Micro-Metastasis *Int. J. Cancer* 131:1071-82, 2012
196. Izraely S, Witz IP. The Metastatic Microenvironment. In: *The Inflammatory Milieu of Tumors.* A. Ben Baruch Editor, Bentham, 3-13, 2012
197. Klein A, Sagi-Assif O, Izraely S, Meshel T, Pasmanik-Chor M, Nahmias C, Couraud PO, Erez N, Hoon DS, Witz IP. The metastatic microenvironment: Brain-derived

- soluble factors alter the malignant phenotype of cutaneous and brain-metastasizing melanoma cells. *Int J Cancer* 131:2509-18, 2012
198. Maman S, Witz IP. The Metastatic Microenvironment. In: *The Tumor Microenvironment*. M. R. Shurin et al. Editors, Springer Science+Business Media, pp.15-38, 2013
 199. Klein-Goldberg A, Maman S, Witz IP. The role played by the microenvironment in site-specific metastasis. *Cancer Lett.* 13: 604-6, 2013
 200. Maman S, Edry-Botzer L, Sagi-Assif O, Meshel T, Yuan W, Lu W, Witz IP. The metastatic microenvironment: lung-derived factors control the viability of neuroblastoma lung metastasis. *Int J Cancer.* 133: 2296-306, 2013
 201. Izraely S, Sagi-Assif O, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Klein A, Prieto VG, Bar-Eli M, Pirker C, Berger W, Hoon DSB and Witz IP. The Metastatic Microenvironment: Claudin-1 Suppresses the Malignancy Phenotype of Melanoma Brain Metastasis *Int J Cancer.* 136:1296-307, 2015
 202. Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, Long GV, Menzies AM, Scolyer RA, Izraely S, Sagi-Assif O, Witz IP, Hoon DS. Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. *J Invest Dermatol.* 135: 532-41, 2015
 203. Klein A, Schwartz H, Sagi-Assif O, Meshel T, Izraely S, Ben-Menachem S, Bengaiev R, Ben-Shmuel A, Nahmias C, Couraud PO, Witz IP, Erez N. Astrocytes facilitate melanoma brain metastasis via secretion of IL-23. *J. Pathol.* 236: 116-27, 2015
 204. Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menachem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud PO, Hoon DS, Witz IP. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. *Cancer Lett.* 361: 86-96, 2015
 205. Lessard L, Liu M, Marzese DM, Wang H, Chong K, Kawas N, Donovan NC, Kiyohara E, Hsu S, Nelson N, Izraely S, Sagi-Assif O, Witz IP, Ma XJ, Luo Y, Hoon DS. The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. *J Invest Dermatol.* 135:2464-74, 2015
 206. Marzese DM, Witz IP, Kelly DF, Hoon DS. Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. *Epigenomics.*7:1303-1311. Epub 2015
 208. Edry-Botzer L, Maman S, Sagi-Assif O, Meshel T, Yron I, Witz IP. Hexokinase 2 is a Determinant of Neuroblastoma Metastasis. *Br J Cancer.* 114:759-66, 2016
 209. Naftali O, Maman S, Meshel T, Sagi-Assif O, Ginat R, Witz IP. PHOX2B is a suppressor of neuroblastoma metastasis. *Oncotarget.* 7:10627-37, 2016
 210. Maman S, Sagi-Assif O, Yuan W, Ginat R, Meshel T, Zubrilov I, Keisari Y, Lu We, Lu Wu and Witz IP. The beta subunit of hemoglobin suppresses tumor growth and metastasis. *Cancer Res.*, 77:14-26, 2017
 211. Klein A, Sagi-Assif O, Meshel T, Telerman A, Izraely S, Ben-Menachem S, Bayry J, Marzese DM, Ohe S, Hoon DSB, Erez N, Witz IP. CCR4 is a Determinant of Melanoma Brain Metastasis. *Oncotarget*, 8:31079-31091, 2017
 212. Wang J, Hirose H, Du G, Chong K, Kiyohara E, Witz IP, Hoon DSB. P-REX1 amplification promotes progression of cutaneous melanoma via the PAK1/P38/MMP-2 pathway. *Cancer Lett*; 407:66-75. 2017
 213. Izraely S, Ben-Menachem S, Sagi-Assif O, Meshel T, Marzese DM, Ohe S, Zubrilov I, Pasmanik-Chor M, Hoon, DSB, Witz IP, ANGPTL4 promotes the progression of cutaneous melanoma to brain metastasis. *Oncotarget*, Advance Publications, July 2017

BOOKS

In situ Expression of Tumor Immunity. Contemporary Topics in Immunobiology, Vol. 10. Isaac P. Witz and M.G. Hanna Jr., Eds., Plenum Press, New York and London, 1980.

The Tumour Microenvironment - Seminars in Cancer Biology, Vol. 12/2, Isaac P. Witz, Guest Editor, 2002

Proceedings of the 2nd International Conference on Tumor Microenvironment, Baden, Austria. Isaac P. Witz, Editor, Monduzzi Editore. Bologna, 2002

Proceedings of the 3rd International Conference on Tumor Microenvironment, Prague, Czech Republic. Isaac P. Witz, Editor, Monduzzi Editore. Bologna, 2004

Proceedings of the 4th International Conference on Tumor Microenvironment, Florence, Italy. Isaac P. Witz, Editor, Monduzzi Editore. Bologna, 2007

Tumor Extravasation and Organ Selectivity of Metastasis – Clinical & Experimental Metastasis, Special issue. Isaac P. Witz, Guest Editor, 2008

The Tumor Microenvironment. Isaac P. Witz, Series Editor. Innate and Adaptive Immunity in the Tumor Microenvironment. Eitan Yefenof Guest Editor. Springer Science+Business Media B.V. 2008

The Tumor Microenvironment. Isaac P. Witz, Series Editor. Regulation of Gene Expression in the Tumor Microenvironment. Menashe Bar-Eli Guest Editor. Springer Science+Business Media B.V. 2008

The Tumor Microenvironment. Isaac P. Witz, Series Editor. From Molecular to Modular Tumor Therapy. Albrecht Reichle Guest Editor. Springer Science+Business Media B.V. 2010

The Tumor Microenvironment. Isaac P. Witz, Series Editor. Tumor-Associated Fibroblasts and their Matrix. Margareta M Mueller, Norbert E Fusenig Guest Editors. Springer Science+Business Media B.V. 2011

The Tumor Microenvironment. Isaac P. Witz, Series Editor. Tumor Ablation. Yona Keisari Guest Editor. Springer Science+Business Media B.V. 2013

ENCYCLOPEDIA OF CANCER 2nd & 3rd Edition (M. Schwab Editor)

Chapter on: Tumor Microenvironment